Physician profile
Monte E Orahood
NPI 1114956414
$7,699.53
in general payments reported to CMS, 2019-2025
38 companies · $847 in 2025
The $847 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $804 · 2020: $1,106 · 2021: $1,532 · 2022: $1,301 · 2023: $1,182 · 2024: $927 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,956.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,520.71 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $832.93 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $555.71 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $545.29 | 2021-2025 | |
| Amarin Pharma, INC. | $459.11 | 2019-2021 | |
| Lilly USA, LLC | $419.80 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $381.54 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $327.05 | 2021-2025 | Xifaxan |
| Amgen INC. | $279.04 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $261.09 | 2019-2023 | |
| Astellas Pharma US INC | $253.79 | 2019-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $232.08 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $201.98 | 2019-2020 | |
| Medtronic, INC. | $184.01 | 2022-2024 | Corevalve Evolut R |
| Janssen Pharmaceuticals, INC | $137.49 | 2021-2023 | Xarelto |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monte Orahood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.